House Dust Mite Allergy - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

House Dust Mite Allergy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H2 2014', provides an overview of the House Dust Mite Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
House Dust Mite Allergy Overview 6
Therapeutics Development 7
Pipeline Products for House Dust Mite Allergy - Overview 7
Pipeline Products for House Dust Mite Allergy - Comparative Analysis 8
House Dust Mite Allergy - Therapeutics under Development by Companies 9
House Dust Mite Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
House Dust Mite Allergy - Products under Development by Companies 13
House Dust Mite Allergy - Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
DBV Technologies SA 15
Stallergenes S.A. 16
Circassia Holdings Ltd. 17
Anergis SA 18
Biomay AG 19
House Dust Mite Allergy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Actair - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
allergenic pollen extract of timothy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MK-8237 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
House Dust Mite-SPIRE - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Subunit Vaccine for Mite Allergy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AllerDM - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Viaskin House Dust Mite - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PL-103 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
House Dust Mite Allergy - Recent Pipeline Updates 37
House Dust Mite Allergy - Dormant Projects 42
House Dust Mite Allergy - Discontinued Products 43
House Dust Mite Allergy - Product Development Milestones 44
Featured News & Press Releases 44
Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 44
Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 44
Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 45
Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 46
Oct 10, 2013: S-TARget Achieves Clinical Proof of Concept for Allergy Vaccine SG100 in Asthmatic Non-human Primates 47
Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction 48
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 48
Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 50
Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 50
Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products under Development for House Dust Mite Allergy, H2 2014 7
Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2014 14
House Dust Mite Allergy - Pipeline by DBV Technologies SA, H2 2014 15
House Dust Mite Allergy - Pipeline by Stallergenes S.A., H2 2014 16
House Dust Mite Allergy - Pipeline by Circassia Holdings Ltd., H2 2014 17
House Dust Mite Allergy - Pipeline by Anergis SA, H2 2014 18
House Dust Mite Allergy - Pipeline by Biomay AG, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H2 2014 37
House Dust Mite Allergy - Dormant Projects, H2 2014 42
House Dust Mite Allergy - Discontinued Products, H2 2014 43